. 2015 Sep 22;15:643. doi: 10.1186/s12885-015-1648-4

Table 2.

Association between clinical variables and objective response by RECIST

Variable		Total n	CR + PR n (%)	SD + PD n (%)	p value
Grade	1 + 2	74	42 (57)	32 (43)	0.01
Grade	3	9	1 (11)	8 (89)	0.01
Mucinous histology	no	84	46 (55)	38 (45)	0.048
Mucinous histology	yes	10	2 (20)	8 (80)	0.048
Liver metastasis	no	31	8 (26)	23 (74)	0.001
Liver metastasis	yes	64	40 (62)	24 (38)	0.001
Peritoneal metastasis	no	79	43 (54)	36 (46)	0.09
Peritoneal metastasis	yes	16	5 (31)	11 (69)	0.09
Chemotherapy	FOLFIRI	52	25 (48)	27 (52)	0.43
Chemotherapy	FOLFOX	39	22 (56)	17 (44)	0.43
Hypertension	no	61	29 (47)	32 (53)	0.41
Hypertension	yes	30	17 (57)	13 (43)	0.41
Chemo + bevacizumab as first-line therapy^a	no	28	9 (36)	19 (64)	0.02
Chemo + bevacizumab as first-line therapy^a	yes	67	40 (60)	27 (40)	0.02

RECIST: Response Evaluation Criteria in Solid Tumors; FOLFIRI: infusional 5-fluoro-uracyl plus leucovorin plus irinotecan; FOLFOX: infusional 5-fluoro-uracyl plus leucovorin plus oxaliplatin; CR: Complete Response; PR: Partial Response; SD: Stable Disease; PD: Progressive Disease (PD). Data are number of patients and numbers in parentheses are percentages. ^aChemo: chemotherapy